January 12-15 | San Francisco Marriott Marquis
January 12-16 | Virtual
Valink Therapeutics
Valink Therapeutics focuses on synergistic and non-obvious target pair combinations to create first-in-class bispecific antibody-drug conjugates (bsADCs) that transform the treatment of solid tumors and other indications.